Even an intermediate degree of left main (LM) disease puts patients with stable, moderate-to-severe CAD at greater risk of adverse events compared with no left main involvement, a subanalysis of the ISCHEMIA trial shows.
In a report released at last week’s Society for Cardiovascular Angiography and Interventions (SCAI) virtual meeting, investigators focused on patients with intermediate LM stenosis (defined as 25% to 49%) as compared to patients with < 25% LM stenosis, representing three-quarters of the trial participants.
|